The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 23, 2010, Pages 7164-7168

  Wang, Jane L ^a   Aston, Karl ^a   Limburg, David ^a   Ludwig, Cindy ^a   Hallinan, Ann E ^a   Koszyk, Francis ^a   Hamper, Bruce ^a   Brown, David ^a   Graneto, Matthew ^a   Talley, John ^a   Maziasz, Timothy ^a   Masferrer, Jaime ^a   Carter, Jeffery ^a  

^a PFIZER INC   (United States)

Author keywords

Benzopyran; Clinical candidate; Cyclooxygenase; Half life; Metabolism; Microdose; Microsomal; Plasma protein bound

Indexed keywords

2 TRIFLUOROMETHYL 2H BENZOPYRAN 3 CARBOXYLIC ACID DERIVATIVE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BENZOPYRAN DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; SC 75416; SD 8381; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BENZOPYRANS; CARBOXYLIC ACIDS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HALF-LIFE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149282305     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.059     Document Type: Article

References (10)

1. The Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.
2. Y. Zhang, A. Shaffer, J. Portanova, K. Seibert, and P.C. Isakson J. Pharmacol. Exp. Ther. 283 1997 1069
3. J.P. Portanova, Y. Zhang, G.D. Anderson, S.D. Hauser, J.L. Masferrer, K. Seibert, S.A. Gregory, and P.C. Isakson J. Exp. Med. 184 1996 883
4. J. Gierse, M. Nickols, K. Leahy, J. Warner, Y. Zhang, L. Cortes-Burgos, J. Carter, K. Seibert, and J. Masferrer Eur. J. Pharmacol. 588 2008 93
5. 50 values with subtle changes in assay protocol.
6. Aston, K. W.; Brown, D. L.; Carter, J. S.; Deprow, A. M.; Fletcher, T. R.; Hallinan, E. A.; Hamper, B. C.; Huff, R. M.; Kiefer, J. R., Jr.; Koszyk, F.; Kramer, S. W.; Liao, S.; Limburg, D.; Springer, J. R.; Tsymbalov, S.; Wang, L. J.; Xing, L.; Yu, Y. WO 04087687 A1, 2004.
7. 2 1 h after dosed the compound.
8. G.W. Caldwell, J.A. Masucci, Z. Yan, and W. Hageman Eur. J. Drug Metab. Pharmacokinet. 29 2004 133
9. European Agency for the Evaluation of Medicines for Human Use (EMEA), Position Paper on the Nonclinical Safety Studies to Support Clinical Trials with a Single Microdose, CPMP/SWP2599/0, Jan 28, 2003.
10. N. Yamanea, Z. Tozuka, Y. Sugiyama, T. Tanimoto, A. Yamazaki, and Y. Kumagai J. Chromatogr. B 858 2007 118